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Serial crystalluria determination and the risk of recurrence in
calcium stone formers.
Background. Urinary crystal precipitation is the necessary
initial step in kidney stone formation. However, clinical rele-
vance of crystalluria in the evaluation of stone formers is dis-
puted.
Methods. We serially determined crystalluria in first-voided
morning urine samples, together with full 24-hour urine bio-
chemistry, in 181 patients with idiopathic calcium nephrolithia-
sis who had formed at least one calcium-oxalate stone and were
followed for at least 3 years under our care. All stone events
which occurred prior to referral, then after entry in the study
were recorded.
Results. As compared with 109 patients who had no evidence
of stone recurrence during follow-up, the 72 patients who expe-
rienced ≥ one recurrent stone event had a lower daily urine
volume (1.74 ± 0.06 vs. 2.26 ± 0.05 L/day (mean ± SEM)
(P < 0.0001), higher urine calcium and oxalate concentrations,
and daily calcium excretion, and they had more frequent crys-
talluria (68% vs. 23% of urine samples) (P < 0.0001). By multi-
variate Cox regression analysis, the hazard ratio for stone recur-
rence was 0.32 (95% CI 0.16-0.62) for 1 L increase in daily urine
volume, 1.12 (1.09-1.24) for 1 mmol/L increase in urine calcium
concentration, 1.24 (1.02-1.50) for 0.1 mmol/L increase in urine
oxalate concentration and 27.8 (10.2-75.6) for crystalluria index.
Conclusion. These data provide evidence that crystalluria,
when repeatedly found in early morning urine samples, is highly
predictive of the risk of stone recurrence in calcium stone for-
mers. Serial search for crystalluria, a simple and cheap method,
may be proposed as a useful tool for the monitoring of calcium
stone formers, in addition to urine biochemistry.
Formation of crystals in urine is the necessary initial
step of lithogenesis in every type of urinary stone dis-
ease. Accordingly, crystal formation is widely used in ex-
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perimental studies aimed at assessing the physicochem-
ical conditions that lead from urine supersaturation to
crystal nucleation, growth, and aggregation [1–6]. How-
ever, if the formation of stones is always preceded by
crystalluria, the reverse is not true and crystalluria may
occur without resulting in stone formation. Therefore,
the clinical relevance of crystalluria in kidney stone for-
mers remains largely debated. Although some authors
proposed crystalluria as an index of stone disease activity
in the early seventies [7, 8], routine search for crystalluria
has not gained widespread popularity in clinical practice
and is not currently recommended in the evaluation of
stone formers. Indeed, because crystalluria is occasion-
ally found in 15% to 20% of healthy, nonlithiasic subjects,
presence of crystals in a single urine specimen was re-
garded as not discriminating between stone formers and
nonstone formers [9, 10]. However, stone formers have
been shown to exhibit more frequent crystalluria, with
larger crystals and more numerous and larger crystal ag-
gregates than healthy subjects [7, 11–17]. Therefore, one
could hypothesize that presence of persistent crystalluria
reflects a propensity for stone formation and may consti-
tute a marker of stone disease activity of potential clinical
relevance.
Since 1984, we performed routinely a search for crys-
talluria, simultaneously with full blood and 24-hour urine
biochemistry, at each visit in all stone former patients re-
ferred to our stone clinic. We subsequently recorded on
line all laboratory data, together with stone episodes, in
our lithiasic patients over the past two decades. We were
thus able to analyze the relationships between serially
determined crystalluria and laboratory parameters and
recurrence of stone episodes in the cohort of consecutive
patients who were referred to us after they had formed
one or several stones. The present study focuses on idio-
pathic calcium oxalate (CaOx) stone formers, who con-
stitute the largest group of our nephrolithiasis patients.
METHODS
Study population
Between January 1984 and December 2000, 651 pa-
tients with idiopathic CaOx urolithiasis were referred to
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our stone clinic. All underwent full blood and 24-hour
urine chemistry evaluation, together with search for crys-
talluria at baseline and at each visit thereafter. Because
the average interval for recurrence was about 3 years in
idiopathic calcium stone formers in previous studies [18,
19], we defined patients as nonrecurrent only if they had
no evidence of formation of new stones for at least 3 years
after referral, whereas patients who suffered recurrent
stone episode(s) where considered whichever the time
duration elapsed from entry in the study until the first
recurrent stone episode. The observation period lasted
until December 2003, in order that each patient had a
follow-up of at least 3 years.
Included in analysis were patients who fulfilled all
of the following criteria: idiopathic CaOx nephrolithia-
sis (CaOx as the main component of stones, with less
than 50% of calcium phosphate in mixed stones); age
>15 years at first stone episode; at least three follow-
up visits with determination of crystalluria; and absence
of any clinical condition or drug therapy that may in-
terfere with calcium metabolism. In particular thiazide
therapy, if any, was withdrawn for at least 15 days prior
to baseline laboratory evaluation. Excluded from analy-
sis were patients with CaOx nephrolithiasis secondary to
defined causes such as primary hyperparathyroidism, pri-
mary hyperoxaluria, enteric hyperoxaluria, renal tubular
acidosis, or systemic diseases, who require specific man-
agement, and patients receiving calcium vitamin supple-
ments or biphosphonates for the prevention or treatment
of postmenopausal osteoporosis. A total of 181 patients
(127 males and 54 females) fulfilled all of these criteria
and constitute the study material. Of them, 141 (78%)
had formed more than one stone or had multiple calculi
before being referred to us, whereas the other 40 (22%)
were first stone formers. Patients with medullary sponge
kidney were considered for analysis. Medullary sponge
kidney was identified on the basis of roentgenologic find-
ings as described elsewhere [20].
Study protocol
After baseline evaluation, all patients were managed
according to a homogeneous protocol aimed at prevent-
ing recurrence of calcium stones. The common basic reg-
imen included high fluid intake to achieve a daily urine
output of at least 2 L, well distributed over day and
night; dietary calcium intake of 800 to 1000 mg/day; mod-
erate consumption of animal proteins and salt; avoid-
ance of oxalate-rich foods, especially chocolate. When
despite these measures hypercalciuria persisted, a thi-
azide diuretic was added, most often in the form of
hydrochlorothiazide (25 mg/day). Allopurinol (200 to
300 mg/day) was prescribed to patients with urinary
urate excretion ≥5 mmol/day. Potassium citrate was used
only in patients with sustained, marked hypocitraturia
(<1 mmol/L).
Clinical surveillance was scheduled at 1 and 3 months
after entry in the study to test the effects of the proposed
regimen and readjust medical treatment when needed,
then every 6 months during the first 2 years, and at yearly
interval thereafter or more frequently if clinically needed.
Radiologic surveillance used serial abdominal plain x-
ray film and echography; in the recent years, spiral com-
puterized tomography was used as indicated. Intravenous
pyelography with low osmolality contrast medium was
obtained at least once in every patient in order to detect
medullary sponge kidney.
Stone episodes ending in spontaneous passage, and
urologic procedures that took place during the prere-
ferral period were recorded with the date of occurrence
and type of urologic procedure used. In addition, we
included in the prereferral stone count asymptomatic
stones present in the urinary tract on baseline radio-
graphic examination. After referral, we prospectively
recorded all symptomatic stone episodes whether they
ended in spontaneous passage or required any uro-
logic procedure. In addition, we included as recurrence
roentgenologic evidence of new stones (i.e., not present
on baseline abdominal x-ray film). We determined the
time elapsed between onset of stone disease (defined as
the date of the first stone episode) and referral, and be-
tween entry in the study and first recurrent stone episode,
or end of the follow-up period (December 31, 2003).
We thus could determine the average annual number of
stones formed by each patient during the prereferral pe-
riod and during the follow-up period.
Laboratory procedures
Twenty-four hour urine collections were obtained at
baseline and at each visit thereafter. A single 24-hour
collection was taken at each visit because a previous
prospective study on 183 calcium stone formers compar-
ing biochemistry parameters in two successive 24-hour
urine collections had shown that the highest number of
abnormalities was found in the first sample in 85% of
cases (unpublished personal data).
Laboratory determinations included 24-hour urine cal-
cium (Ca), phosphate, oxalate (Ox), citrate, magnesium,
urea, creatinine, uric acid, sodium, and potassium to-
gether with specific gravity. Plasma concentrations of the
same parameters (except oxalate and citrate) were simul-
taneously determined.
Based on the common observation that urine produced
during the night is usually the most concentrated, and
therefore carries the highest risk of supersaturation and
crystal formation, we performed all crystalluria studies
in fresh first-voided morning urine samples, according to
a uniform protocol described elsewhere [21]. In short,
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urine samples brought to the laboratory within 2 hours of
voiding were kept at room temperature and were rapidly
processed. Urine-specific gravity and pH were measured.
Undiluted urine was then homogeneized by gentle shak-
ing and turning over (neither centrifuged nor filtered) and
immediately placed in a Malassez cell (CML, Nemours,
France) containing 10 mm3, then examined by light
microscopy using a polarizing microscope (Optiphot-2)
(Nikon, Champigny-sur-Marne, France). The entire cell
was examined at ×200 magnification to localize crys-
tals and aggregates, then with ×400 magnification (high
power field). All crystals and aggregates were counted
on the entire cell and their size determined using the
included micrometric scale. The results were expressed
as number of crystals by mm3. Only one Malassez cell
was examined in each instance. Crystalluria examinations
were performed in a “blind” manner (i.e., without knowl-
edge of the clinical status of the patients and of the results
of laboratory determinations). We did not consider small
calcium phosphate grains less than 2 lm in diameter. The
mean number of crystalluria studies beyond the baseline
one was 6.8 ± 5.3 per patient, with a median of five de-
terminations (range 3 to 33). We defined as “crystalluria
index” the ratio of the number of urine samples with crys-
talluria to the total number of examined urine samples.
The average value of all 24-hour urine biochemistry pa-
rameters was used in the follow-up period.
Statistical analysis
Data are presented as means ± SEM unless otherwise
specified. Intergroup comparisons used Student t test,
Mann-Whitney test, or analysis of variance (ANOVA)
for continuous variables, and the v 2 and Fisher’s exact
tests for categoric variables. Differences in medians for
not normally distributed parameters were compared us-
ing Mann-Whitney U or Wilcoxon rank sum test.
The primary outcome measure was the time from en-
try in the study until first recurrence of a renal stone, or
study end in non-recurrent patients. Secondary outcomes
were the total number of recurrent stones formed and the
total number of urologic procedures required during the
follow-up period. Cox proportional hazards regression
analysis used the time duration until first recurrence as
end point. Univariate study examined the influence of
previous stone disease activity (number of stones/year in
the prereferral period), age at start of stone disease, daily
urine volume, 24-hour urinary parameters at baseline and
during follow-up, and proportion of serial first-voided
urine specimens with presence of crystalluria as continu-
ous variables during follow-up. Gender and presence of
medullary sponge kidney were entered as categoric vari-
ables. Only parameters with a P < 0.10 significance were
entered in the final multivariate analysis.
Table 1. Characteristics of the 181 patients in the prereferral and
follow-up periods
Prereferral Follow-up
period period
Duration years 8.7 ± 0.7 6.8 ± 0.3
Number of stone episodes
Mean number/patient 4.83 ± 0.45 1.07 ± 0.14a
Number/patient-year 0.67 ± 0.07 0.21 ± 0.03a
Number of spontaneous passages 3.39 ± 0.43 0.82 ± 0.12a
Number of urologic procedures (total) 1.42 ± 0.13 0.18 ± 0.04a
Total number of urologic procedures 256 34
Open surgery (%) 79 (30.8) 0
Percutaneous nephrolithotomy 12 (4.7) 4 (11.8)
Extracorporeal shock wave lithotripsy 114 (44.5) 22 (64.7)
Ureteroscopy 51 (19.9) 8 (23.5)
Data are given as mean ± SEM. Comparison follow-up period vs. prereferral
period (Mann-Whitney test)
aP < 0.0001.
Receiver operating characteristics (ROC) curve analy-
sis was used to determine the cut-off values of significant
variables with respect to the risk of stone recurrence.
All P values are two-sided. A P value < 0.05 was con-
sidered significant. Statistical procedures used the NCSS
2000 software (Jerry L. Hintze, Kaysville, UT, USA).
RESULTS
The studied cohort comprised 181 patients, all Cau-
casian (127 males and 54 females). There was a marked
male preponderance with a gender ratio of male to fe-
male of 2.35. A family history of urolithiasis was found
in 75 patients (41.4%), and medullary sponge kidney was
present in 76 patients (42%).
At baseline, 38.6% of patients (56.6% of those with
medullary sponge kidney and 33.4% of those without
medullary sponge kidney) had one or more renal stones at
radiographic evaluation; 66.3% were hypercalciuric at re-
ferral (calcium excretion ≥0.1 mmol/kg/day on free diet
in both genders) and 49.7% had a daily urine volume
≤1.5 L.
As shown on Table 1, the overall number of stone
episodes significantly decreased in the follow-up period
as compared to the prereferral period. The number of
stone episodes ending in spontaneous passage declined
from 3.39 ± 0.43 to 0.82 ± 0.12 per patient (P < 0.0001),
a decrease of 76%, and the number of urologic proce-
dures from 1.42 ± 0.13 to 0.18 ± 0.04 per patient (P <
0.0001), a decrease of 86.5%. As a result, the total num-
ber of formed stones, (including three asymptomatic new
stones formed during follow-up) decreased from 4.83 ±
0.45 to 1.07 ± 0.14 stone/patient (a reduction by 78%)
between the prereferral and the follow-up period. All
urologic procedures were fewer than in the prereferral
period, and in particular no open surgery was performed
after referral.
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Table 2. Characteristics of patients with (R) and without (NR) stone recurrence during the follow-up period
NR R
(N = 109) (N = 72) P value
Gender Male/female 74/35 53/19 0.41
Mean age at first stone episode years 32 (15–68) 28 (15–64) 0.027
Number with medullary sponge kidney (%) 34 (31.2) 42 (58.3) 0.001
Number with family history (%) 41 (37.6) 34 (47.2) 0.20
Prereferral period
Duration years 7.5 (0.1–33) 5.0 (0.1–25) 0.36
Number of spontaneously passed stones/patient 2.80 ± 0.44 4.28 ± 0.85 0.09
Number of urologic procedures/patient 1.40 ± 0.17 1.43 ± 0.22 0.92
Number of stone episodes per patient-year 0.53 ± 0.09 0.89 ± 0.13 0.02
At referral
Mean age at referral years 44 (20–72) 36 (15–71) 0.0003
Body mass index kg/m2 23.8 ± 0.33 23.3 ± 0.40 0.33
Serum creatinine at referral lmol/L 89.7 ± 1.38 90.2 ± 2.1 0.85
Number of single stone formers (%) 25 (22.9) 15 (20.8) 0.74
Number of stone-free patients at referral (%) 61 (55.9) 47 (65.3) 0.21
Mean urine volume L/day 1.6 (0.8–3.3) 1.4 (0.6–2.9) 0.0001
Patients with urine volume ≤1.5 L/day (%) 44 (40.4) 46 (63.9) 0.003
Urine calcium concentration mmol/L 3.9 (0.9–12) 6.0 (2.2–12) <0.0001
Urine calcium excretion mmol/day 6.4 (1.8–16.4) 7.9 (3.4–15.6) 0.0019
Urine calcium excretion mmol/kg/day 0.11 (0.02–0.23) 0.13 (0.02–0.21) 0.017
Hypercalciuria ≥0.1 mmol/kg/day (%) 63 (57.8) 57 (79.2) 0.003
Urine oxalate concentration mmol/L 0.24 (0.09–0.62) 0.27 (0.10–0.47) 0.07
Urine oxalate excretion mmol/day 0.40 (0.13–0.88) 0.36 (0.11–0.67) 0.18
Urine citrate concentration mmol/L 1.8 (0.2–4.8) 1.9 (0.1–5.8) 0.24
Urine citrate excretion mmol/day 2.7 (0.3–7.4) 2.8 (0.1–6.1) 0.64
Urine urea excretion mmol/day 388 (160–757) 397 (192–674) 0.42
Urine urea excretion mmol/kg/day 5.9 (2.3–8.7) 5.9 (2.3–10.2) 0.78
Follow-up period
Duration years 6.88 ± 0.41 6.79 ± 0.53 0.90
Number treated with thiazide (%) 42 (38.5) 26 (36.1) 0.74
Time to first recurrence years — 2.41 ± 0.14
Number of spontaneous passage/patient 0 2.07 ± 0.25
Number of urologic procedures/patient 0 0.46 ± 0.09
Number of recurrences/patient 0 2.67 ± 0.25
Number of recurrences/patient-year 0 0.37 ± 0.05
Average urine volume L/day 2.1 (1.2–4.0) 1.7 (0.7–2.8) <0.0001
Patients with urine volume ≥2 L/day (%) 73 (66.9) 16 (21.1) <0.0001
Urine calcium concentration mmol/L 2.4 (0.5–6.7) 4.2 (1.7–9.1) <0.0001
Urine calcium excretion mmol/day 5.3 (1.8–15.1) 7.1 (2.6–13.4) <0.0001
Urine oxalate concentration mmol/L 0.20 (0.06–0.37) 0.27 (0.10–0.49) <0.0001
Urine oxalate excretion mmol/day 0.44 (0.16–0.98) 0.43 (0.19–0.93) 0.79
Urine citrate concentration mmol/L 1.3 (0.3–3.5) 1.6 (0.1–4.5) <0.007
Urine citrate excretion mmol/day 2.9 (0.4–6.5) 2.8 (0.1–5.5) 0.48
Urine urea excretion mmol/day 403 (180–656) 382 (175–643) 0.59
Urine urea excretion mmol/kg/day 5.7 (2.3–10.6) 5.8 (2.2–10.1) 0.89
Number of crystalluria determinations 4 (3–28) 5 (3–33) 0.53
Mean crystalluria index 0.23 ± 0.03 0.68 ± 0.03 <0.0001
Crystalluria in ≥50% of samples (%) 17 (15.6) 63 (87.5) <0.0001
Serum creatinine at end of follow-up lmo/L 92 ± 2 93 ± 2 0.60
Data are given as mean (± SEM) for normally distributed parameters and as medians (with range) for not normally distributed parameters.
During follow-up, 72 patients experienced at least one
recurrent stone episode (R group) whereas the other 109
remained free of any recurrence for at least 3 years af-
ter entry in the study (NR group). Characteristics of pa-
tients in the R and NR groups are given in Table 2. The
two groups did not differ with respect to gender distribu-
tion, family history of stones, proportion of single stone
formers, presence of stones at baseline, body mass index
(BMI), and proportion of patients treated with thiazide,
but age of patients at clinical onset of urolithiasis was sig-
nificantly lower in the R than in the NR group. Patients in
the R group had a higher stone disease activity in the pre-
referral period (0.89 ± 0.13 stone episodes/patient-year)
than did NR patients (0.53 ± 0.09) (P = 0.02), whereas
the number of required urologic procedures was similar.
During the follow-up period, R patients experienced
a significantly lesser incidence of stone episodes as com-
pared with their corresponding prereferral period (0.37
± 0.05 vs. 0.89 ± 0.13 episodes/patient-year) (P < 0.001),
and the number of required urologic procedures also de-
creased significantly.
At baseline, daily urine output was significantly lower
and daily calcium excretion was significantly higher in the
R than in the NR group, whereas daily oxalate and citrate
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excretion did not differ, nor urinary urea excretion. The
difference was even more marked when considering urine
calcium concentration.
During follow-up, the average daily urine output rose
in both R and NR groups, but to a lesser extent in the
former than in the latter. The mean increase in daily
urine volume was close to 0.5 L/day in the NR group,
as compared with only about 0.3 L/day in the R group.
The mean average daily urine output during follow-up
was thus markedly higher in NR than in R patients (2.26
± 0.05 vs. 1.74 ± 0.06 L/24 hours) (P < 0.0001).
Mean daily urine calcium excretion decreased in both
groups, but more markedly so in the NR group. As a re-
sult of both higher diuresis and lower calcium excretion,
urine calcium concentration was strikingly lower in NR
than in R patients (2.47 ± 0.10 vs. 4.36 ± 0.19 mmol/L)
(P < 0.0001). In contrast, average daily oxalate excretion
did not significantly differ from the prereferral period,
and was similar in the R and NR groups. However, ox-
alate concentration decreased in the NR group, but not
in the R group, and thus was significantly lower in the
former than in the latter during follow-up. Average daily
citrate excretion remained unchanged with respect to the
prereferral period in both groups, and did not differ be-
tween R and NR groups, but urinary citrate concentra-
tion was higher in the R group, thus reflecting a lower
diuresis. Urea excretion remained essentially unaltered
in both groups, and did not differ between R and NR
groups during follow-up.
Crystalluria was found in a significantly higher propor-
tion of urine samples in R than in NR patients (68 ± 3
vs. 23 ± 3%) (P < 0.0001). Of note, presence of crys-
talluria at baseline or occurrence of crystalluria during
follow-up did not differ whether or not patients had pre-
existing stones. Crystalluria was found in 45% of urine
samples of stone-free patients and in 38% of those with
renal stone(s) present at baseline or during follow-up (a
not significant difference). Overall, crystalluria was found
in ≥50% of individual urine samples in 87.5% of R pa-
tients, as compared to 15.6% of NR patients, a highly
significant difference (P < 0.0001).
The mean time from entry in the study to first recur-
rence was 2.4 ± 1.2 years (median 2.3 and range 0.5 to 5
years) in the R group, whereas no recurrence was ob-
served in the NR group over a mean follow-up dura-
tion of 6.9 ± 4.2 years (range 3 to 15 years). By ROC
curve analysis, the cut-off values for the risk of develop-
ing stone recurrence during follow-up were as follows: av-
erage follow-up urine output 1.94 L/day [sensitivity 0.69,
specificity 0.76, and positive predictive value (PPV) 0.82;
negative predictive value (NPV) 0.62; and area under the
curve (AUC) 0.78]; average follow-up urine calcium con-
centration 3.78 mmol/L (sensitivity 0.71, specificity 0.88,
PPV 0.80, NPV 0.82, and AUC 0.88), and crystalluria in-
dex 0.50 (sensitivity 0.88, specificity 0.84, PPV 0.79, NPV
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Fig. 1. Receiver operating characteristic (ROC) curve for the risk of
stone recurrence with respect to crystalluria index.
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Fig. 2. Receiver operating characteristic (ROC) curve for the risk of
stone recurrence with respect to average daily urine volume during
follow-up (protective effect).
0.91, and AUC 0.88). The ROC curves for crystalluria
and urine volume versus stone recurrence are shown in
Figures 1 and 2.
As compared with the 105 CaOx stone formers without
medullary sponge kidney, the 76 patients with medullary
sponge kidney had a more severe stone disease (Table 3).
Their mean number of stone episodes was nearly three
times higher both before and after referral, and the pro-
portion of medullary sponge kidney patients with recur-
rence of stone formation was nearly two times higher.
Nevertheless, a striking reduction in the number of symp-
tomatic stone episodes and even more in the number of
required urologic procedures was observed after entry in
the medical protocol by comparison with the prereferral
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Table 3. Data on calcium oxalate (CaOx) stone formers with or without medullary sponge kidney
Without medullary sponge kidney With medullary sponge kidney
(N = 105) (N = 76) P value
Prereferral
Number of stone episodes/patient 2.99 ± 0.28 7.38 ± 0.94 <0.0001
Number of urologic procedures/patient 1.31 ± 0.15 1.55 ± 0.24 0.38
At referral
Baseline urine calcium excretion mmol/day 7.1 (1.9–16.4) 6.9 (1.8–15.6) 0.59
Baseline daily urine volume L/day 1.6 (0.6–3.3) 1.45 (0.8–3.4) 0.03
Follow-up
Number with stone recurrence (%) 30 (28.5) 42 (55.3) 0.0003
Number of stone episodes/patient 0.55 ± 0.10 1.76 ± 0.28 <0.0001
Number of urologic procedures/patient 0.12 ± 0.05 0.26 ± 0.07 0.10
Average urine volume L/day 2.1 (0.7–3.9) 1.9 (0.9–3.5) 0.002
Urine calcium excretion mmol/day 6.4 (1.8–15.1) 5.6 (1.8–12.7) 0.25
Urine oxalate excretion mmol/day 0.44 (0.16–0.99) 0.42 (0.18–0.93) 0.39
Urine citrate excretion mmol/day 2.9 (0.4–9.5) 2.8 (0.1–6.3) 0.78
Crystalluria index 0.38 ± 0.03 0.45 ± 0.04 0.15
Results are expressed as in Table 2.
Table 4. Univariate Cox regression analysis for the risk of recurrence
Risk factors Z value Hazard ratio (95% CI) P value
Age at onset (per 1 year) −2.38 0.98 (0.96–0.99) 0.017
Medullary sponge kidney (present) 3.73 2.45 (1.53–3.92) 0.0002
Family history (present) 1.73 1.15 (0.98–1.34) 0.08
Baseline urine volume (per 1 L/day) −3.52 0.36 (0.20–0.63) 0.0004
Baseline calcium excretion (per 1 mmol/day) 2.18 1.07 (1.01–1.15) 0.029
Baseline calcium concentration (per 1 mmol/day) 4.81 1.24 (1.14–1.36) <0.0001
Crystalluria index 8.64 35.8 (15.9–80.7) <0.0001
Crystalluria in ≥50% of samples 7.69 15.8 (7.8–31.8) <0.0001
Follow-up urine volume (per 1 L) −6.66 0.17 (0.10–0.29) <0.0001
Follow-up calcium excretion (per 1 mmol/day) 4.28 1.18 (1.09–1.28) <0.0001
Follow-up calcium concentration (per 1 mmol/L) 8.29 1.62 (1.45–1.82) <0.0001
Follow-up oxalate excretion (per 100 pmol/day) 0.32 1.28 (0.29–5.76) 0.75
Follow-up oxalate concentration (per 100 lmol/L) 6.02 2.32 (1.76–3.05) <0.0001
Follow-up citrate excretion (per 1 mmol/day) −0.40 0.97 (0.81–1.15) 0.69
Follow-up citrate concentration (per 1 mmol/L) 0.97 1.15 (0.87–1.54) 0.33
period. Urine lithogenic parameters did not differ be-
tween patients with or without medullary sponge kidney;
crystalluria was found more frequently in the former, but
the difference did not reach statistical significance.
Results of univariate Cox regression analysis are given
in Table 4. Age at onset of stone disease, presence of
medullary sponge kidney, baseline urine volume, base-
line urine calcium excretion and concentration, as well as
average follow-up urine volume, daily calcium excretion,
urine Ca and Ox concentrations, and crystalluria were
significantly associated with the risk of stone recurrence.
Results of multivariate Cox regression analysis for the
whole series are given in Table 5. We entered in multivari-
ate Cox regression analysis only presence of medullary
sponge kidney, and average follow-up values of daily uri-
nary volume, Ca and Ox concentrations, and crystalluria
index, because there were strong correlations between
baseline and follow-up daily urine volume and between
daily excretion and concentration of Ca and Ox, as well
as between crystalluria index and presence of crystals in
≥50% of samples. Follow-up average daily urine param-
eters were selected as reflecting the effects of preventive
measures implemented after referral.
In this model, five factors were significantly and inde-
pendently associated with the risk of recurrence: presence
of medullary sponge kidney, follow-up Ca and Ox con-
centrations, follow-up daily urine volume and crystalluria
index. The latter revealed the most powerful predictor of
stone recurrence, with a hazard ratio of nearly 28 whereas
presence of crystalluria in at least half of urine samples
was associated with a hazard ratio of 16.8. Urine volume
was the second most powerful factor, with the risk of re-
currence decreasing by 68% for each 1 L/day increase in
daily urine output.
When limited to the subgroup of 76 patients with
medullary sponge kidney, multivariate Cox regression
analysis identified as independent risk factors for recur-
rence only three parameters: average daily urine output
[hazard ratio (HR) 0.40 per 1 L/day (95%CI 0.15-0.99)]
(P = 0.041), average calcium concentration [HR 1.30 per
1 mmol/L (95% CI 1.08-1.56)] (P < 0.005), and crystal-
luria [HR 26.2 (95% CI 11.1-86.2)] (P < 0.0001).
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Table 5. Multivariate Cox regression analysis based on average follow-up values
Risk factors Z value Hazard ratio (95% CI) P value
Presence of medullary sponge kidney 2.97 2.15 (1.30–3.56) 0.003
Follow-up calcium (per 1 mmol/L) 2.12 1.12 (1.09–1.24) 0.03
Follow-up urine volume (per 1 L/day) −3.35 0.32 (0.16–0.62) 0.0008
Crystalluria index 6.51 27.8 (10.2–75.6) <0.0001
Follow-up oxalate (per 0.1 mmol/L) 2.20 1.24 (1.02–1.50) 0.028
DISCUSSION
The present study is the first to analyze in parallel the
association of serially determined crystalluria and urine
biochemistry parameters with CaOx stone recurrence in
a long-term, prospective cohort study. Our data provide
strong evidence that frequent crystalluria (i.e., found in
at least half of first morning urine samples) is the most
reliable indicator of the risk of recurrence in CaOx stone
formers.
Our working hypothesis was that repeated finding of
crystalluria in a patient should reflect the risk of sustained
crystallization, leading to stone formation. To gain clinical
relevance, this hypothesis had to be verified by means of a
prospective study based on the record of all newly formed
stones in a cohort of stone formers followed over a long
time duration. We elected to study first-voided, morning
urine samples because they have been shown to exhibit
the highest concentration of solutes and therefore are at
highest risk of containing crystals [22, 23].
The population analyzed in this study is not represen-
tative of common stone formers populations and does
not reflect our own whole cohort of calcium stone for-
mers nor the proportion of recurrent patients. Due to
our status of tertiary referral center, our cohort presents
an overrepresentation of severe, relapsing forms of idio-
pathic CaOx urolithiasis and especially of patients with
medullary sponge kidney. Indeed, 78% of patients al-
ready were recurrent stone formers when referred to us,
66% were hypercalciuric, and 42% had medullary sponge
kidney as underlying condition. Medullary sponge kidney
has been shown to be associated with an especially high
rate of stone production [20, 24, 25] and this was the case
in the present series. In the whole population of 651 pa-
tients with idiopathic calcium nephrolithiasis evaluated at
our stone clinic from 1984 to 2000, medullary sponge kid-
ney accounted for a markedly less proportion (25.1%). In
addition, only patients with at least 3 years of follow-up
were included in order to reliably assess nonrecurrence
as several studies showed that time duration until first
recurrence was about 3 years [18, 19]. There was a high
rate of drop out of follow-up with time among patients, as
already observed by Parks, Asplin, and Coe [19]. A pos-
sible explanation is that patients with a less severe form
were more prone to neglect medical surveillance than pa-
tients with frequent recurrences, such as those with MSK.
Although most of our patients had a rather severe form
of nephrolithiasis, an overall improvement was observed,
with a global reduction in stone formation by 77% during
follow-up as compared with the prereferral period, even
in medullary sponge kidney patients. Of note, a decreased
recurrence frequency was also observed in the R group,
with a mean annual incidence of stone episodes reduced
by 58%, and of urologic procedures by 67% as compared
with the prereferral period.
Our patients were managed according to a homoge-
neous protocol over the whole study period. In view of
the report of Bataille et al in 1983 [26], we adopted in 1984
the recommendation of dietary calcium intake of no less
than 600 mg/day, and following the study of Curhan et al
in 1993 [27], we prescribed a calcium intake of 800 to 1000
mg/day to all of our calcium stone formers. Based on the
data of Robertson et al [28] we recommended since the
early 1980s a moderate animal protein and salt intake.
Based on the findings of Pak et al [29] and Hosking et
al [30] we recommended all stone formers to maintain a
high fluid intake, ensuring a daily urine output of at least
2 L, well distributed over night and day.
In this regard, our present data confirm and extend pre-
vious observations on the primary importance of urine di-
lution for preventing stone recurrence. Pak et al [29] were
the first to formally demonstrate that urine dilution sig-
nificantly increases the formation product ratio of CaOx,
thus reducing the risk of crystal nucleation. Borghi et al
[31] observed that increasing nocturnal urine volume by a
500 mL water load administered at 11:30 p.m. resulted in
nearly halving the CaOx relative supersaturation in both
normal controls and normocalciuric CaOx stone form-
ers. On a clinical point of view, Hosking et al [30] ob-
served that, among stone formers with a similar initial
urine volume, those who exhibited no recurrence during
follow-up had a significantly higher daily urine volume
than those who had recurrent stone formation (about 2.1
vs. 1.7 L/day). In large epidemiologic studies comparing
dietary habits and incidence of stones in cohorts of men or
women aged ≥40 years without history of renal colic, the
risk of kidney stones was inversely correlated with fluid
intake [27, 32]. Subsequently, Curhan et al [33] examined
24-hour urine chemistries in 913 subjects diagnosed with
a first kidney stone compared with 309 healthy controls
randomly sampled from the same cohorts. Mean daily
urine volume was lower in cases than in controls in either
gender. In a prospective randomized interventional study
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in 199 male CaOx stone formers, Borghi et al [34] showed
that patients who sustained a urine volume >2 L/day, in-
stead of <1.1 L/day, had a significantly lower incidence of
recurrent stone formation over a 5-year follow-up period.
Our study highlights the importance of a high urine
volume to prevent CaOx stone recurrence, and confirms
the validity of the universal recommendation to increase
urine volume to at least 2 L/day [35, 36]. The mean av-
erage urine volume during follow-up in our NR group
was 2.26 L/day, compared to 1.74 L/day in the R group,
and ROC curves identified a daily output of 1.94 L as the
cut-off value.
In agreement with the findings of Curhan et al [33],
we found that baseline 24-hour urinary calcium excretion
was significantly higher in the R than in the NR group.
The difference was even more marked when consider-
ing urine calcium concentration, which was nearly 50%
higher in the R than in the NR group, an observation
in keeping with the lower mean baseline urine volume
in the R group. Moreover, the mean increment in urine
output was higher (by nearly 500 mL/day) in NR patients,
compared to only 300 mL/day in R patients, whose base-
line diuresis already was about 250 mL/day lower than
in patients who subsequently had no recurrence during
follow-up. It has been suggested that part of CaOx stone
formers spontaneously have a weak thirst, and therefore
a low fluid intake and suboptimal urine volume, thus re-
sulting in a higher risk of recurrence [37]. As a matter of
fact, oligodipsia was declared by two thirds of our patients
with a spontaneously low urine volume. On a practical
point of view, this finding highlights the importance of
motivating stone formers to achieve and sustain a urine
volume of at least 2 L/day, with fluid intake at bedtime in
order to avoid nocturnal urine hyperconcentration.
Hypercalciuria, hyperoxaluria, and hypocitraturia
have been shown to act as the main lithogenic factors
in idiopathic calcium urolithiasis [38–40]. However, most
studies were based on the calculation of urinary CaOx
supersaturation, which is a theoretic criterion of the risk
of crystallization and stone formation. Only two studies,
including one by Curhan et al [33] and the present one,
provide a multivariate analysis of the association of uri-
nary parameters with the more relevant criterion of symp-
tomatic stone episodes. The case/control study of Curhan
et al [33] concluded to a significant, graded correlation
between incidence of stones and both daily urine volume
and calcium excretion, but not with citrate, oxalate, or
uric acid excretion. The most critical lithogenic determi-
nant appeared as the urine concentration of calcium. Our
data, based on the incidence of recurrent stone episodes
in a cohort of patients all of whom had a history of stones,
are fully concordant. We observed a significant influence
on stone recurrence of daily urine volume and of calcium
(but not oxalate or citrate) excretion, and of Ca and Ox
urinary concentrations, giving clinical confirmation to our
previous observation that CaOx crystallization in urine is
in close relationship with the CaOx molar product [41].
The positive relationship between stone recurrence and
oxalate concentration found in our patients suggests that
calcium stone formers may be more sensitive to oxalate
concentration to form CaOx crystals than normal sub-
jects, in agreement with the results of crystalluria studies
reported by Fan and Chandhoke [42].
Many indices have been proposed to evaluate the risk
of being a stone former. They are mostly based on 24-hour
urine biochemistries, such as the saturation-inhibition in-
dex proposed by Robertson et al [43], the relative CaOx
supersaturation by Equil 2 computerized software [44],
or the AP(CaOx) index proposed by Tiselius et al [45],
and other indices [46]. However, even if such indices are
able to discriminate between cohorts of nonstone forming
healthy subjects and of stone formers, there is consider-
able overlapping in the values of these indices at the indi-
vidual level. In contrast, serial crystalluria determination
revealed a simple and reliable method to assess the risk
of recurrence in individual stone formers. The strength of
our study relies on its prospective design, with long-term
follow-up of a cohort of patients managed according to
a homogeneous protocol and followed with serial deter-
minations of both urine biochemistry and crystalluria.
Frequency of the finding of crystalluria was strikingly
higher in recurrent stone formers than in their nonrecur-
rent counterparts, and appeared as a stronger predictive
index of recurrent stone formation than were biochem-
istry parameters. However, neither crystal number and
size nor presence of aggregates allowed discrimination
between recurrent and nonrecurrent stone formers. Of
note, crystalluria was not influenced by the presence of
kidney stones, as crystalluria was not found more fre-
quently in patients with stones present in the kidneys at
baseline or during follow-up than in those who remained
stone free. This finding has the important implication that
crystalluria may be used as a marker of stone disease ac-
tivity irrespective of the presence or absence of stone(s)
in the kidney.
The positive and negative predictive values of crystal-
luria index for a cut-off value of 0.5 as determined by
ROC curve analysis could be influenced by the preva-
lence of the exposure. Indeed, not surprisingly, the num-
ber of crystalluria determinations was slightly higher in
the R group than in the NR group, thus reflecting that pa-
tients with recurrences were more frequently seen than
those free of recurrence. In any case, it remains that crys-
talluria was the most powerful predictor of the risk of
recurrence.
Assessment of crystalluria appears of clinical interest in
the management of idiopathic calcium stone formers, as
already shown in patients with cystinuria [47] or primary
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hyperoxaluria [48]. Indeed, crystalluria globally reflects
the risk of stone formation as it integrates the complex
interactions between promoters and inhibitors of litho-
genesis, both known and unknown, either measurable or
not. In clinical practice, finding of crystals in the morn-
ing urine sample should alert the physician that one or
several urinary lithogenic factors determined by urine
chemistry analysis are not adequately controlled. Such a
finding suggests considering daily urine volume and dis-
tribution together with excretion of calcium, oxalate, uric
acid, citrate, magnesium, urea, and sodium excretion, in
order to readjust dietary measures and institute or rein-
force targeted drug therapy. In particular, finding of CaOx
crystals in the first morning urine sample together with a
high specific gravity highly suggests an excessive concen-
tration of urine during the night, thus requiring increased
fluid intake at bedtime. In addition, evidence of crystal-
luria contributes to motivate the patient to comply with
recommendations.
In our patients, recurrence of stones was consistently
preceded by the persistence or reappearance of crystal-
luria. Based on this finding, reinforcement of preventive
measures, especially increase and/or better distribution
of fluid intake, was usually followed by vanishing of crys-
talluria in parallel with arrest of stone recurrence.
Medullary sponge kidney appeared as an aggravat-
ing condition, as manifested by a higher spontaneous
incidence of stone episodes than in patients without
medullary sponge kidney and a higher proportion of re-
currences during follow-up as observed by others [24,
25], despite similar baseline and follow-up values of daily
urine volume and calcium excretion. As indicated by
multivariate analysis, the protective effect of increased
urine volume was less apparent than in the whole se-
ries, thus suggesting that a higher daily urine volume is to
be achieved in medullary sponge kidney patients to re-
duce the risk of stone recurrence. This finding highlights
the role of mechanic factors superimposed to metabolic
ones [20], and confirms the need for hyperdiuresis in
medullary sponge kidney patients in order to maximally
reduce urine CaOx supersaturation and accelerate urine
flow.
CONCLUSION
Our study provides evidence that crystalluria is highly
indicative of stone disease activity in CaOx stone form-
ers, and predictive of stone recurrence especially when
repeatedly present in urine samples. In our experience,
the predictive value of crystalluria was much greater than
that of daily urine volume, 24-hour calcium excretion, or
even urine calcium or oxalate concentration, the most in-
fluent factors in CaOx stone formers, thus indicating that
other known or still unidentified factors contribute to the
risk of CaOx stone formation. Indeed, crystal precipita-
tion is the resultant of all factors, both promoters and
inhibitors, measured and unmeasured, acting in urine to
trigger crystal formation, the first step in lithogenesis. Be-
cause crystalluria study is a reliable, simple, and cheap
method, serial crystalluria determination may be pro-
posed as a useful clinical tool in the monitoring of CaOx
stone former patients, in addition to urine biochemistry.
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